Jubilant Ingrevia LimitedQ1 FY27 Results & Financial Update
Jubilant Ingrevia Limited: Q1 FY27 consolidated results and company financials – revenue ₹1,300.27 Cr, PAT ₹105.82 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Jubilant Ingrevia price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Jubilant Ingrevia Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
For the quarter ended June 30, 2026, Jubilant Ingrevia reported total consolidated revenue from operations of Rs 1,300.27 crore, alongside total income of Rs 1,310.49 crore.
Profit before tax (PBT) for Q1 FY27 stood at Rs 140.86 crore, reflecting solid operational performance across core chemical segments and improved realization environments.
Net profit for the period (PAT) reached Rs 105.82 crore, translating to basic earnings per share of Rs 6.70 and diluted EPS of Rs 6.68 for the quarter.
Total expenses for the quarter aggregated to Rs 1,169.60 crore, driven by material consumption of Rs 717.68 crore and power and fuel expenses of Rs 138.46 crore.
The company maintained a healthy debt-service coverage ratio of 4.81 times and an interest service coverage ratio of 12.01 times on a consolidated basis.
Net worth expanded to Rs 3,241.45 crore as of June 30, 2026, with a conservative net debt-to-equity ratio of 0.22 times.
Profit after tax was ₹105.82 Cr for the reported quarter. EPS was ₹6.68 for the reported quarter.
01 · Business model
What does Jubilant Ingrevia do?
Jubilant Ingrevia Limited operates as an integrated life science ingredients and chemical solutions provider, manufacturing custom research and manufacturing services, specialty chemicals, nutrition and health solutions, and chemical intermediates.
The company's operating footprint is structured around three primary segments: Speciality Chemicals, Nutrition & Health Solutions, and Chemical Intermediates, supplying global life sciences, animal nutrition, crop protection, and industrial sectors.
Manufacturing operations are anchored by large-scale production facilities in India, notably at Gajraula in Uttar Pradesh, supported by extensive feedstock integration and continuous chemical processing capabilities.
02 · Historical context
What shaped the business before this quarter
Previously, the company expanded its subsidiary network, including the addition of Remidex Pharma Private Limited as a subsidiary effective March 30, 2026.
During the previous year, effective November 21, 2025, the Government of India consolidated multiple labour legislations into four new Labour Codes, resulting in an exceptional employee benefit impact of Rs 13.04 crore in FY26.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹1,300.27 Cr |
| Total income | ₹1,310.49 Cr |
| Profit before tax | ₹140.86 Cr |
| Profit after tax | ₹105.82 Cr |
| EPS | ₹6.68 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 8.1% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 10.8% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹10.22 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Consolidated gross segment revenue before inter-segment eliminations reached Rs 1,405.99 crore, led by Speciality Chemicals at Rs 637.00 crore and Chemical Intermediates at Rs 525.17 crore.
Nutrition & Health Solutions contributed gross revenue of Rs 243.82 crore for the quarter, demonstrating steady demand in animal nutrition and health formulations.
What drove margins
The consolidated operating margin for the quarter was reported at 11.39%, supported by optimized cost structures and operating leverage across chemical processing lines.
Cost of materials consumed stood at Rs 717.68 crore, while power and fuel expenses accounted for Rs 138.46 crore, reflecting energy-intensive operations at manufacturing sites.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Speciality Chemicals segment revenue (net of inter-segment eliminations) stood at Rs 532.74 crore, delivering a segment result (PBIT) of Rs 109.14 crore.
Chemical Intermediates recorded net segment revenue of Rs 524.07 crore and a segment result (PBIT) of Rs 43.97 crore.
Nutrition & Health Solutions reported net revenue of Rs 243.46 crore with a segment result (PBIT) of Rs 28.26 crore.
06 · Strategy & new businesses
How the company is trying to change its growth mix
During the quarter ended June 30, 2025, the company granted 343,569 stock options to eligible employees under its stock option plans administered by the Nomination, Remuneration and Compensation Committee.
07 · Reported developments
What changed operationally
Consolidated net profit for the quarter rose to Rs 105.82 crore, reflecting robust demand across core chemical and intermediate portfolios.
08 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
The consolidated current ratio stood at 1.24 times as of June 30, 2026, with debtors turnover at 1.52 times and inventory turnover at 0.64 times for the quarter.
Capital allocation & funding
Total debt to total assets ratio remained conservative at 0.15 times, with finance costs for the quarter recorded at Rs 17.43 crore.
09 · Beyond the numbers
What changed beyond the numbers
Reported update
Statutory auditor review
The financial results for the quarter ended June 30, 2026, were subjected to a limited review by statutory auditors Walker Chandiok & Co LLP, who issued an unmodified conclusion.
10 · Key Q&A
The quarter, answered directly
What does Jubilant Ingrevia do?
Jubilant Ingrevia Limited operates as an integrated life science ingredients and chemical solutions provider, manufacturing custom research and manufacturing services, specialty chemicals, nutrition and health solutions, and chemical intermediates.
What is the clearest takeaway from Q1 FY27?
For the quarter ended June 30, 2026, Jubilant Ingrevia reported total consolidated revenue from operations of Rs 1,300.27 crore, alongside total income of Rs 1,310.49 crore.
What drove revenue or demand?
Consolidated gross segment revenue before inter-segment eliminations reached Rs 1,405.99 crore, led by Speciality Chemicals at Rs 637.00 crore and Chemical Intermediates at Rs 525.17 crore.
What mattered most for margins or profitability?
The consolidated operating margin for the quarter was reported at 11.39%, supported by optimized cost structures and operating leverage across chemical processing lines.
What changed operationally beyond the headline numbers?
During the quarter ended June 30, 2025, the company granted 343,569 stock options to eligible employees under its stock option plans administered by the Nomination, Remuneration and Compensation Committee.
What should the next disclosure help confirm?
The company continues to monitor developments regarding the Code of Wages (Central) Rules, 2026, notified on May 8, 2026, to evaluate further financial impacts.
11 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
12 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Labour Code rules monitoring: The company continues to monitor developments regarding the Code of Wages (Central) Rules, 2026, notified on May 8, 2026, to evaluate further financial impacts.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.